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Current antiretroviral therapies for HIV-1 are not curative
because a small number of CD4þT-cells remain infected with a
latent, replication-competent provirus that contributes to viral
rebound after the cessation of therapy. Several approaches to
purge persistent HIV-1 reservoirs are in the beginning phases of
clinical trials. To ensure future curative therapies target replica-
tion-competent HIV-1 proviruses for eradication, a thorough
understanding of the distribution of replication-competent HIV-
1 within T-cell subsets and how activation and proliferation of
these cells contribute to the maintenance of the replication-
competent HIV-1 reservoir is required. This study will employ a
full-length single-proviral sequencing assay based on Next
Generation Sequencing (NGS) techniques to sequence the entire
HIV-1 genome of proviruses isolated from CD4þT-cell subsets
(central, transitional, and effector) sorted from peripheral blood
and lymphoid tissue after 5–15 years of suppressive therapy
from two groups of participants (1) three participants who initi-
ated therapy during acute/early infection and (2) three partici-
pants who initiated therapy during chronic infection.
Replication-competent proviruses will be identified by the
absence of deletions and APOBEC3G induced hypermutation.
The infection rates of replication-competent proviruses located
in specific cell populations between participants will be com-
pared along with the frequencies of replication-competent pro-
viruses between different T-cell populations and within tissue-
derived cells from these participants. This important study will
allow us to determine whether specific cellular compartments
harbour replication-competent HIV-1 and will provide valuable
information for future curative HIV-1 clinical trials.
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HIV-1 non-B subtype infections have been observed in Belgium
since the 1980s. However, subtype B predominates amongst
men having sex with men (MSM), whereas other subtypes are
mainly associated with sub-Saharan African migrants and het-
erosexual risk behavior. In the last decade, subtype F1 diagnoses
have increased substantially in Belgium, representing 9% of
newly diagnosed and therapy-naı̈ve HIV-1 patients linked to
care in 2014. In the present study, the Belgian subtype F1 epi-
demic has been characterized within a global context, where F1
is responsible for<1% of HIV-1 infections. The Belgian AIDS
Reference Laboratories collected HIV-1 pol sequences from
patients linked to care and sub-subtype F1 was verified using
Rega v3 and COMET v1.0 subtyping tools. Concordant F1
sequences were retained from 293 patients, who were diag-
nosed with HIV-1 between 1988 and 2015. The number of F1
diagnoses increased from three in 2001–2 to 83 in 2013–4.
Seventy-seven percent were men, with 52% homosexual, 15%
bisexual, and 15% heterosexual contact as the probable trans-
mission route (18% not registered). Belgium was the probable
country of infection for 54% of the patients, whereas for 38%
this information was not registered. A reference dataset from
countries with a high burden of F1 infections or with a potential
role in the global origin of sub-subtype F1 was collected from
public and private databases and the phylogeny was recon-
structed using RAxML and BEAST. These analyses indicate that
190 Belgian F1 sequences, 97% from men, and 72% with homo-
sexual/bisexual risk behavior (17% not registered), belong to a
monophyletic group with two sub-clades. Together with a
Spanish clade, the Belgian clade is embedded in the Brazilian
subtype F1 diversity and probably emerged after single or two
migration events from South-America with one dead-end line-
age (2 strains) and one actively spreading cluster (188 strains).
This study reconstructed the structure of the local HIV-1 F1 epi-
demic and showed that onward transmission of subtype F1
occurs extensively among MSM. It illustrates the introduction
and dissemination of strains in one geographically restricted
risk group in which the subtype was previously absent.
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In Slovenia, as in many Western countries, subtype B is still a
predominant HIV-1 subtype and was historically correlated
with the epidemic among men who have sex with men (MSM).
In recent years, several reports demonstrating an increasing
prevalence of non-B subtypes have been published. The major-
ity of infections with non-B subtypes were linked to the hetero-
sexual mode of transmission in previous Slovenian studies,
thus the aim of this study was to investigate whether non-B
subtypes are also becoming more prevalent among MSM in
Slovenia. Between the years 2000 and 2014, a total of 520 people
were diagnosed with HIV-1 infection in Slovenia. During the
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